Formulation and Evaluation of In-situ Ophthalmic Gel of Ketorolac Tromethamine

Authors

  • Dipen R. Bhimani
  • Daya L. Chothani

Keywords:

Ketorolac tromethamine, In-situ gel, Sustained release, Ophthalmic delivery

Abstract

Low bioavailability, frequent dosage, and rapid precorneal excretion are the drawbacks of conventional ketorolac tromethamine eye drops. These drawbacks can be overcome by in-situ ophthalmic gels, which extend ocular residence and offer prolonged drug release. Using poloxamer 188 and poloxamer 407 as thermos-responsive gelling agents, the current study sought to create and assess a sustained release in-situ ocular gel containing ketorolac tromethamine. Using varying concentration of poloxamer 188 and poloxamer 407 integrated as a gelling agent, several formulations were created. Clarity, pH, gelling capacity, and in-vitro drug release were assessed for the produced gels. To ensure gelation at ocular physiological temperature, the optimized formulation including poloxamer 407 and poloxamer showed a sol-to-gel transition at approximately 34.7°C. For long-term precorneal retention, the gel displayed pseudoplastic flow with sufficient viscosity. According to in-vitro release experiments, ketorolac tromethamine exhibits a sustained release that can last for up to 12 hours. The work shows that ketorolac tromethamine can be safely and effectively delivered using in-situ gels based on poloxamers 188 and 407. These formulations are a possible substitute for traditional eye drops in the treatment of ocular inflammation and pain because they can increase ocular bioavailability, decrease dose frequency, and improve patient compliance

Downloads

Download data is not yet available.

References

1) Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–360.

2) Le Bourlais C, Acar L, Zia H, Sado PA, Needham T, Leverge R. Ophthalmic drug delivery systems: Recent advances. Prog Retin Eye Res. 1998;17(1):33–58.

3) Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131–1135.

4) Lee VHL, Robinson JR. Topical ocular drug delivery: Recent developments and future challenges. J Ocul Pharmacol. 1986;2(1):67–108.

5) Lang JC. Ocular drug delivery: Conventional ocular formulations. Adv Drug Deliv Rev. 1995;16(1):39–43.

6) Srividya B, Cardoza RM, Amin PD. Sustained ophthalmic delivery of ofloxacin from a pH-triggered in situ gelling system. J Control Release. 2001;73(2–3):205–211.

7) Miller SC, Donovan MD. Effect of Poloxamer 407 gel on the miotic activity of pilocarpine nitrate in rabbits. Int J Pharm. 1982;12(2–3):147–152.

8) Rozier A, Mazuel C, Grove J, Plazonnet B. Gelrite®: A novel, ion-activated, in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol. Int J Pharm. 1989;57(2):163–168.

9) Cohen S, Lobel E, Trevgoda A, Peled Y. A novel in situ-forming ophthalmic drug delivery system from alginates undergoing gelation in the eye. J Control Release. 1997;44(2–3):201–208.

10) Gratieri T, Gelfuso GM, de Freitas O, Rocha EM, Lopez RFV. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Eur J Pharm Biopharm. 2011;79(2):320–327.

11) Fathalla ZMA, Vangala A, Longman M, Khaled KA, Hussein AK, El-Garhy OH, et al. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterization, toxicity and transcorneal permeation studies. Eur J Pharm Biopharm. 2017;114:119–134.

12) Gillis JC, Brogden RN. Ketorolac: A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs. 1997;53(1):139–188.

13) McGhee CNJ. Pharmacokinetics of ophthalmic corticosteroids. Br J Ophthalmol. 1992;76(11):681–684.

14) Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197–1216.

15) Schoenwald RD, Ward RL. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J Pharm Sci. 1978;67(6):786–788.

16) Pignatello R, Bucolo C, Spedalieri G, Maltese A, Puglisi G. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. Biomaterials. 2002;23(15):3247–3255.

17) Almeida H, Amaral MH, Lobão P, Sousa Lobo JM. Applications of poloxamers in ophthalmic pharmaceutical formulations: An overview. Expert Opin Drug Deliv. 2013;10(9):1223–1237.

18) Fathalla ZMA, Vangala A, Longman M, Khaled KA, Hussein AK, El-Garhy OH, et al. Poloxamer-based thermoresponsive ketorolac tromethamine in situ gel preparations: Design, characterization, toxicity and transcorneal permeation studies. Eur J Pharm Biopharm. 2017;114:119–134.

19) Fathalla ZMA, Khaled KA, Hussein AK, Alany RG, Vangala A. Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles. Drug Dev Ind Pharm. 2016;42(4):514–524.

20) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Harmonised Tripartite Guideline Q1A(R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.

21) Rokhade AP, Agnihotri SA, Patil SA, Mallikarjuna NN, Kulkarni PV, Amin TM. Semi-interpenetrating polymer network microspheres of gelatin and sodium carboxymethyl cellulose for controlled release of ketorolac tromethamine. Carbohydr Polym. 2006;65(3):243–252.

22) Newa M, Bhandari KH, Oh DH, Kim YR, Sung JH, Kim JO, et al. Enhanced dissolution of ibuprofen using solid dispersion with Poloxamer 407. Arch Pharm Res. 2008;31(11):1497–1507.

23) Thakor S, Vhora I, Desai J, Thakkar S, Thakkar H. Physiologically activated phase transition systems for improved ocular retention of ketorolac tromethamine. J Pharm Bioallied Sci. 2012;4(Suppl 1):S38–S39.

24) Dumortier G, Grossiord JL, Agnely F, Chaumeil JC. A review of Poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm Res. 2006;23(12):2709–2728.

25) El Sayeh FA, El Khatib MM. Formulation and evaluation of new long-acting metoprolol tartrate ophthalmic gels. Saudi Pharm J. 2014;22(6):555–563.

26) Ricci EJ, Bentley MVB, Farah M, Bretas RES, Marchetti JM. Rheological characterization of Poloxamer 407 lidocaine hydrochloride gels. Eur J Pharm Sci. 2002;17(3):161–167

Downloads

Published

2023-12-20

How to Cite

1.
R. Bhimani D, Chothani DL. Formulation and Evaluation of In-situ Ophthalmic Gel of Ketorolac Tromethamine. J Neonatal Surg [Internet]. 2023 Dec. 20 [cited 2026 Sep. 22];12(1):248-60. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10480

Issue

Vol. 12 (2023): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.